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ABSTRACT
Allogeneic hematopoietic cell transplantation (HCT) is the only curative strategy for patients with myelodys-
plastic syndrome (MDS) and myeloproliferative disorders (MPD).We report the results of 148 patients (median
age5 59 years old) with de novoMDS (n5 40), acutemyelogenous leukemia (AML) after antecedentMDS/MPD
(n 5 49), treatment-related MDS (t-MDS) (n 5 25), MPD (n 5 27), and chronic myelomonocytic leukemia
(CMML) (n 5 7) who underwent allogeneic HCT using a conditioning regimen of low-dose total body irradia-
tion (TBI) alone (200 cGy) on day 0 (n5 5) or with the addition of fludarabine (Flu) 30 mg/m2/day on days24 to
22 (n 5 143). Postgrafting immunosuppression consisted of cyclosporine and mycophenolate mofetil (MMF).
Seventy-five patients (51%) received an allograft from a matched related donor (MRD), and 73 patients (49%)
were recipients of unrelated donor (URD) grafts. There was no significant difference in the incidence of acute
(gr II-IV) and chronic extensive graft-versus-host disease (aGVHD, cGVHD) between the recipients of related
and unrelated donor grafts. By day128, 75% of patients demonstrated mixed T cell chimerism. Graft rejection
was seen in 15%of patients.With amedian follow-up of 47 (range: 6-89)months, the 3-year relapse-free survival
(RFS) and overall survival (OS) are both 27% for all patients, with a relapse incidence of 41%. The 3-year RFS for
the patients with de novoMDS, AML after antecedent MDS/MPD, t-MDS, MPD, and CMML were 22%, 20%,
29%, 37%, and 43%, respectively, and the 3-year OS was 20%, 23%, 27%, 43%, and 43%, respectively. The
3-year nonrelapse mortality (NRM) was 32%. Factors associated with a lower risk of relapse were the develop-
ment of extensive cGVHD and having a low risk or intermediate-1 risk International Prognostic Score for the de
novoMDS patients. Nonmyeloablative HCT confers remissions in patients who otherwise were not eligible for
conventional HCT but for whom relapse is the leading cause of treatment failure.
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The myelodysplastic syndromes (MDS) and mye-
loproliferative disorders (MPD) are clonal hematopoi-
etic stem cell (HSC) disorders that have the potential246for evolution to acute myelogenous leukemia (AML).
Allogeneic hematopoietic cell transplantation (HCT)
is currently the only therapy with curative potential,
but most patients are of advanced age with attendant
Allogeneic Reduced Intensity Conditioning 247comorbidities, which has limited the number of pa-
tients who are eligible for myeloablative regimens fol-
lowed by allogeneic HCT. Nonrelapse mortality
(NRM) can be prohibitive, especially in the elderly,
and in patients with advanced disease can be as high
as 80% [1-5]. Thus, reduced-intensity (RIC) or non-
myeloablative regimens have been increasingly offered
because these treatment modalities induce engraft-
ment with low toxicity. Nonmyeloablative HCT relies
on graft-versus-tumor effects and has proved safe and
efficacious in various hematologic malignancies.
This report describes the characteristics and out-
comes of 148 consecutive adult patients with MDS or
MPD from 14 institutions who received a nonmyeloa-
blative conditioning regimen of low-dose total body
irradiation (TBI) with or without fludarabine before
HCT from HLA-matched or mismatched related or
unrelated donors (URDs). The patients were not suit-
able candidates for conventional myeloablative condi-
tioning because of age or comorbid conditions.
METHODS
This analysis includes data from 148 patients diag-
nosed with MDS andMPD who underwent allogeneic
HCT after nonmyeloablative conditioning on multi-
institutional protocols for patients with hematologic
malignancies between January 1998 and November
2004. The primary differences between protocols were
theuseofHLA-matched relatedorunrelatedgrafts, var-
iations in the duration and intensity of CSP and MMF,
and the addition of fludarabine to 2 Gy TBI. These
changes were made over time to reduce both the risks
of GVHD and graft rejection. The study protocols
and written informed consents were approved by the
institutional review boards (IRB) of the participating
institutions. Results were analyzed as of April 30, 2007.
The 14 participating centers included FredHutch-
inson Cancer Research Center (n5 50), Stanford Uni-
versity Medical Center (n5 33), University of Leipzig
(n 5 18), Baylor University Medical Center (n 5 10),
Seattle Veterans Affairs Puget Sound Health Care
System (n 5 10), Oregon Health Sciences University
(n 5 6), University of Utah (n 5 5), City of Hope
National Medical Center (n 5 4), Emory University
(n 5 3), Medical College of Wisconsin (n 5 3), Uni-
versity of Colorado (n 5 2), University of Torino (n
5 2), University of Tuebingen (n5 1), and University
of Arizona (n5 1) on prospective multicenter research
protocols. The initial results of 38 of the 50 patients
from the Fred Hutchinson Cancer Research Center
have been described previously, and this current anal-
ysis includes an update of their results [6].
Patients aged .49 years and\75 years old were
eligible. However, patients\50 years at high risk for
regimen-related toxicity using amyeloablative regimen
were also allowed. Included in this study were patientswith MDS, including the diagnoses of refractory
anemia (RA), refractory anemia with ringed sidero-
blasts (RARS), chronic myelomonocytic leukemia
(CMML), refractory anemia with excess blasts
(RAEB), refractory anemia with excess blasts in trans-
formation (RAEB-T), and MDS transformed
to AML. Patients with advanced MDS and evolution
to AML were cytoreduced to \10% marrow blasts.
Patients with MPD who were eligible for this study
included polycythemia vera (PV) and essential
thrombocythemia (ET) with persistent thrombotic or
hemorrhagic complications despite conventional
therapy or who had progressed to marrow fibrosis.
Patients with agnogenic myeloid metaplasia (AMM)
with\10% marrow blasts or\5% blasts if evolution
to AML were also included. Treatment-related MDS
patients had prior cytotoxic chemotherapy for
previously diagnosed malignancies or autoimmune
diseases.
In a subset of patients who were MRD recipients
(n 5 39), diagnosis was classified as ‘‘indolent’’ or
‘‘aggressive’’ for the purposes of determining rate of cy-
closporine taper, which is further explained under the
‘‘Treatment and Evaluations’’ section of this report.
Indolent disease was defined as (1) MDS with FAB
diagnosis of RA or RARS; (2) CMML; (3) atypical
CML in chronic phase; (4) PV or ET in proliferative
phase or spent phase with or without myelofibrosis,
without excess blasts (\10% marrow blasts); (5)
AMM; and (6) acute leukemia with antecedent MDS
or MPD induced to complete remission. Aggressive
disease was defined as (1) MDS with an FAB diagnosis
of RAEB or RAEB-T prior to cytoreductive therapy,
(2) CMML with excess blasts or in blastic transforma-
tion prior to cytoreductive therapy, (3) atypical CML
with excess blasts or in transformation prior to cytore-
ductive therapy, (4) PV or ET in blastic transformation
prior to cytoredutive therapy, (5) AMM in blastic
transformation prior to cytoreductive therapy, and
(6) acute leukemia with antecedent MDS or MPD.
Exclusion criteria were creatinine clearance \50
mL/min, ejection fraction \40% (symptomatic for
congestive heart failure requiring therapy, poorly con-
trolled cardiac arrythmias, or poorly controlled hyper-
tension were exclusion criteria), diffusing lung carbon
monoxide (DLCO)\50% of predicted value, severe
liver dysfunction (liver failure, cirrhosis, uncorrectable
hepatic synthetic dysfunction, and symptomatic biliary
disease or total bilirubin .3 mg/dL), Karnofsky per-
formance status of \60%, active CNS involvement
of disease, treatment refractory fungal infections, or
active bacterial infections.
HLA Typing
Donors were HLA-matched as defined by the
following criteria: (1) matched for HLA-DRB1 and
DQB1 by high resolution typing; (2) serologically
248 G. G. Laport et al.matched for all recognized HLA-A, -B, and –C anti-
gens and molecularly matched for at least 5 of 6
HLA-A, -B, or -C antigens by high-resolution typing.
One hundred thirty-five patients received HLA-
matched grafts; 11 patients received grafts mismatched
for a single class I HLA allele; 1 graft was mismatched
for 2 class I HLA alleles and 1 graft was mismatched at
a single class I HLA antigen. All of the mismatched
grafts were among the recipients of URD grafts.
Treatment and Evaluations
One hundred forty-three patients were treated
with 3 doses of fludarabine (Flu) 30 mg/m2/day from
days24 to22 and a single fraction of 2 Gy TBI deliv-
ered at a 0.07 Gy/min from linear accelerators on day
0. Five related recipients received 2 Gy of TBI without
flu. Hematopoietic cells were infused in the afternoon
of day 0. One hundred forty-five patients received
granulocyte-colony stimulating factor (G-CSF) mobi-
lized allogeneic peripheral blood hematopoietic cells,
whereas 4 unrelated recipients received marrow grafts.
Cyclosporine (CSP) was administered orally at a dose
of 6.25 mg/kg twice daily from day23 targeting whole
blood trough levels of 500-600 mg/dL. The antici-
pated stop date of CSP was determined by disease
risk in 39 patients as previously mentioned. For the re-
cipients of related grafts, patients in the ‘‘indolent’’ risk
category started the CSP taper on day1100 with a tar-
get stop date by day1177, whereas patients in the ‘‘ag-
gressive’’ disease risk category initiated the CSP taper
on day156 with a targeted stop day of day181. For all
other MRD recipients, CSA was either stopped by day
56 (n 5 33) or day 1180 (n 5 3). For unrelated recip-
ients, the CSP taper was initiated at day 1100 with
a target stop date of day 1180. CSP was stopped ear-
lier if progressive disease occurred. GVHD prophy-
laxis also included MMF 15 mg/kg by mouth twice
daily, beginning on day 0 after hematopoietic cell infu-
sion and discontinued on day 128 without a taper in
related recipients. The unrelated recipients received
MMF 15 mg/kg by mouth every 8-12 hours on the
evening of day 0, with a taper starting day 140 with
a target stop date of day196. TheMMFdosing sched-
ule of every 8 hours was based on previously published
data showing less graft rejection in unrelated recipients
compared to every 12 hour dosing [7,8].
GVHD Grading and Therapy and Supportive Care
All occurrences of acute or chronic GVHD
(aGVHD, cGVHD) were graded according to estab-
lished criteria [9,10]. Treatment was provided for
grade II-IV aGVHD, which included CSP 5 mg/kg
by mouth twice a day or 1.5 mg/kg i.v. twice a day to
aim for therapeutic levels. Prednisone 2 mg/kg/day
was added for grade II-IV GVHD at the discretion
of the treating physician. Steroid-refractory aGVHDwas treated per institutional practice. Prophylaxis
against infections was implemented according to the
standard practice of the individual transplant center.
Follow-up
Patients were examined by a healthcare provider in
the outpatient department during the period of neu-
tropenia per institutional guidelines. Bone marrow
aspirates were performed for histology, cytogenetic
analysis, and chimerism on day 128, 156, 184, and
1180, and then annually. Percentages of donor-host
chimerism were evaluated by fluorescein in situ
hybridization (FISH) for X and Y chromosomes if
patients and donors were sex mismatched or by poly-
merase chain reaction-based amplification of variable
number of tandem repeat sequences unique to donors
and hosts if patients and donors were sex matched.
Mixed chimerism was defined as between 5% and
95% peripheral blood donor T cells, and full chime-
rism was defined as .95% donor T cells. After day
156 and if patients were clinically stable, routine eval-
uation including a history and physical exam, complete
blood counts, and serum chemistry panel were per-
formed at 3, 4, 6, 9, 12, and 18 months, then at 2 years
and yearly thereafter.
Treatment of Persistent, Progressive, or Relapsed
Diseases and Prevention of Graft Rejection
Patients with progressive disease or persistent dis-
ease were eligible for donor lymphocyte infusion
(DLI) as therapeutic intervention. Declining chime-
rism was also considered an indication for DLI admin-
istration. Patients with any grade (II-IV) aGVHD or
extensive cGVHD were not eligible for DLI. Other
eligibility criteria to receive DLI included completion
of immunosuppression taper for 1-2 weeks before DLI
administration and presence of at least mixed hemato-
poietic chimerism as defined by .5% donor periph-
eral blood T cells. Patients who had developed
GVHD (except grade 1 aGVHD or limited cGVHD)
must have successfully completed GVHD therapy for
8 weeks beforeDLI was given. If a patient had progres-
sive disease, consideration was given toward early dis-
continuation of immunosuppression as a first line
intervention.
Statistical Methods
Survival curves were estimated according to the
Kaplan-Meier method. Overall survival (OS) was
defined as time from transplantation to death of any
cause. Relapse-free survival (RFS) was defined as
time from transplantation to relapse, progression, or
death of nonrelapse causes. Cumulative incidence
estimates were calculated for aGVHD, cGVHD,
relapse/progression, and NRM. Deaths were treated
as competing events in analyses of graft rejection,
GVHD, and disease progression. Univariate and
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were performed using Cox regression. The relation-
ship between rejection and aGVHD and cGVHD
with subsequent outcomes was assessed by treating
these factors as time-dependent covariates.
RESULTS
Patient Characteristics
Characteristics for all patients and for each disease
subtype are listed in Tables 1 and 2. The median age
for all patients was 59 (range: 26-73) years. The 5 dis-
ease subtypes were AML after antecedent MDS/MPD
(n 5 49), de novo MDS (n 5 40), treatment-related
MDS (n 5 25), MPD (n 5 27), and CMML (n 5 7).
The patients with de novo MDS were divided into 2
subsets for the purposes of analysis: low/intermedi-
ate-1 and intermediate-2/high. Seventy-five patientswere recipients of HLA-matched related donor
(MRD) grafts (51%) and 73 patients (49%) received
grafts from URD. Regarding hematopoietic cell
source, 144 patients received G-CSF mobilized
peripheral blood hematopoietic cells and 4 patients
received bone marrow. The median CD341 cell dose
was 6.9  106/kg (range: 1.0-34) and median CD31
cell dose was 2.7 108/kg (range 0.17-26).Median fol-
low-up after HCT for alive patients was 47 (range:
6-89) months.
Chimerism, Engraftment and Rejection
One hundred forty-two patients survived to day
128 and 129 patients were assessed for T cell chime-
rism at that time. Of these evaluable patients, only 5
(4%) failed to achieve $5% donor T cell chimerism.
Four of these 5 patients relapsed (at days 27, 35, 113,Table 1. Patient Characteristics
All patients
(n 5 148)
AML after
Antecedent
MDS/MPD (n 5 49)
De Novo
MDS (n 5 40)
t-MDS
(n 5 25)
MPD
(n 5 27)
CMML
(n 5 7)
Patient age,
median (range)
59 (26-73) 62 (26-72) 60 (42-72) 56 (46-73) 58 (27-73) 58 (39-62)
Time from
diagnosis to HCT in months,
median (range)
11 (2-223) 9 (2-142) 11 (3-165) 6 (3-223) 14 (3-157) 10 (3-32)
Patient age, n (%)
\60 years old 78 (53%) 19 (39%) 20 (50%) 18 (72%) 17 (63%) 4 (57%)
$60 years old 70 (47%) 30 (61%) 20 (50%) 7 (28%) 10 (37%) 3 (43%)
Donor relation, n (%)
MRD 75 (51%) 24 (49%) 23 (58%) 12 (48%) 11 (41%) 5 (71%)
URD 73 (49%) 25 (51%) 17 (43%) 13 (52%) 16 (59%) 2 (29%)
Patient sex, n (%)
Male 98 (66%) 32 (65%) 28 (70%) 14 (56%) 20 (74%) 4 (57%)
Female 50 (34%) 17 (35%) 12 (30%) 11 (44%) 7 (26%) 3 (43%)
Donor sex, n (%)
Male 75 (51%) 22 (45%) 20 (50%) 12 (48%) 18 (67%) 3 (43%)
Female 73 (49%) 27 (55%) 20 (50%) 13 (52%) 9 (33%) 4 (57%)
Prior autologous HCT, n (%)
No 130 (88%) 49 39 (98%) 9 (36%) 26 (96%) 7
Yes 18 (12%) 0 1 (3%) 16 (64%) 1 (4%) 0
Prior myelosuppresive
chemotherapy, n (%) (unknown
for 3 patients)
No 61 (42%) 7 (15%) 28 (72%) 2 (8%) 22 (85%) 2 (29%)
Yes 84 (58%) 41 (85%) 11 (28%) 23 (92%) 4 (15%) 5 (71%)
In CR at transplant, n (%) (unknown
for 17 patients)
No 90 (69%) 14 (33%) 30 (86%) 17 (71%) 23 (96%) 6
Yes 41 (31%) 28 (67%) 5 (14%) 7 (29%) 1 (4%) 0
IPSS group, n (%) (unknown for 1
de novo MDS patient)
Low — — 22 (56%) — — —
High — — 17 (44%) — — —
MDS indicates myelodysplastic syndrome; t-MDS, treatment-related myelodysplastic syndrome; AML, acute myelogenous leukemia after an-
tecedent myelodysplastic syndrome or myeloproliferative disorder; MPD, myeloproliferative disorder; CMML, chronic myelomonocytic
leukemia; CR, complete remission; HCT, hematopoietic cell transplantation; IPSS, International Prognostic Scoring System; MRD,
matched related donor; URD, unrelated donor.
250 G. G. Laport et al.and 174) and the other died of nonrelapse causes on
day 141. Of these 5 patients, 1 patient had received
TBI only as the conditioning regimen with the other
4 receiving both TBI plus flu. Twenty-three (16%)
patients rejected their grafts with a median time to re-
jection of 72 days. Rejection was an adverse risk fac-
tor for both OS (hazard ratio [HR] 5 2.40, 95%
confidence interval [CI] 1.5-3.9, P 5 .001) and RFS
(HR 5 2.86, 95% CI 1.6-5.1, P 5 .002). There was
no difference in rejection incidences between the un-
related (16%) and the related (15%) recipients.
CD31 cell dose, CD341 cell dose, and prior HCT
also did not impact incidence of rejection. Younger
age, prior myeloablative chemotherapy, and trans-
Table 2. Diagnoses and Subtypes
De novo myelodysplastic syndrome 40
IPSS
Low 7
Intermediate-1 15
Intermediate-2 12
High 5
Unknown 1
FAB
Refractory anemia 18
Refractory anemia with ringed sideroblasts 3
Refractory anemia with excess blasts 16
Unknown 3
Myeloproliferative disorder 27
Idiopathic myelofibrosis 12
Chronic myelogenous leukemia 3
Essential thrombocythemia 4
Polycythemia vera 1
Undifferentiated 7
Chronic myelomonocytic leukemia 7
Treatment-related MDS 25
Prior autologous HCT 18
Prior myeloablative HCT 1
Prior conventional chemotherapy 6
MDS indicates myelodysplastic syndrome;HCT, hematopoietic cell
transplantation; IPSS, International Prognostic Scoring System;plant in remission were associated with lower risk
of rejection in univariate analysis; however, none of
these factors had significant associations in multivar-
iate analysis.
Five patients received DLI, 3 for progressive dis-
ease and 2 for declining T cell chimerism at a median
of 219 (range: 154-762) days following HCT. The
median CD31 cell dose infused was 26  107/kg
(range: 1  107/kg – 1  108/kg). Three of the DLI
products were collected at steady state (unmobilized)
and the other 2 products were G-CSF mobilized.
Two patients subsequently died from progressive dis-
ease: 1 died from sepsis and 1 succumbed to hepatic
GVHD. One of the patients is alive and in remission
from refractory anemia at 6 years after HCT after
receiving DLI for declining chimerism.
Acute and Chronic GVHD
The incidences of aGVHD and cGVHD by donor
source are listed in Table 3. Fifty-seven patients (39%)
developed grade II-IV aGVHD. Median time to the
diagnosis of aGVHDwas 41 days. There was no differ-
ence in incidences of aGVHD or cGVHD by donor
source (MRD versus URD). aGVHD was the cause
of death in 24 (16%) patients (11 with unrelated and
13 with related donors). Seventy-one patients devel-
oped cGVHD, which was extensive in 55 patients,
with a cumulative incidence at 2 years of 37%. The
median time to extensive cGVHD was 141 days.
Patients with extensive cGVHD experienced signifi-
cantly less relapse (HR 5 0.42, 95% CI 0.2-1.0, P 5
.04). We separately analyzed the subset of 39 MRD
recipients in which CSA taper varied according to
the ‘‘indolent’’ (n 5 10) versus ‘‘aggressive’’ (n 5 29)
disease risk category and found no significant differ-
ences in incidence of aGVHD, cGVHD, or relapse;
however, the small sample size limits our ability to
conclude that differences do not exist.Table 3. Patient Outcomes
All Patients
(n 5 148)
AML after
Antecedent
MDS/MPD (n 5 49)
De Novo
MDS (n 5 40)
t-MDS
(n 5 25)
MPD
(n 5 27)
CMML
(n 5 7)
Primary endpoints
Overall survival
at 3 years
27% 20% 23% 27% 43% 43%
Relapse-free survival
at 3 years
27% 22% 20% 29% 37% 43%
Relapse at 3 years 41% 49% 40% 40% 26% 57%
NRM at 200 days 21% 20% 23% 16% 30% 0%
NRM at 3 years 32% 29% 40% 31% 37% 0%
GVHD endpoints MRD URD P-value
Acute grade II-IV 36% 40% .31
Acute grade III-IV 11% 10% .99
Extensive chronic 43% 32% .31
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With a median follow-up of 47 months, 37 of 148
(25%) patients are alive. ThemedianOS andRFSwere
180 days and 296 days, respectively. Table 3 and
Figures 1-3 demonstrate patient outcomes by disease
subgroup. For the 40 patients with de novo MDS, no
significant differences were seen in RFS or NRM
(P5 .07 and .68, respectively) between the low/interme-
diate-1 group and the intermediate-2/high groups, but
the latter group had a significantly higher incidence of
relapse/progression (HR5 2.92, 95% CI 1.0-8.6, P5
.04; see Figures 4 and 5). Relapse was the leading cause
of death (55%). The median time to relapse was 113
days. Prior autologous HCT did not affect NRM
even though these patients were heavily pretreated.
Patients with chemotherapy-induced remissions
before HCT did not have superior survival or progres-
sion incidences compared to patients who did not
receive pre-HCT chemotherapy. In univariate analy-
sis, factors significantly associated with relapse/pro-
gression were the occurrence of clinical extensive
cGVHD (see above) and, among patients with de novo
MDS, an IPSS risk score of intermediate-2 or higher
(HR 5 2.92, 95% CI 1.0-8.6, P 5 .04; see Table 4).
In multivariate analysis, being in CR at the time of
transplantation was associated with decreased relapse
risk (HR 5 0.47, 95% CI 0.2-1.0, P 5 .05); no other
factors were significantly associated with any outcome.
Regimen-Related Toxicities and Infections
The NRM for all patients at 200 days and 3 years
was 21% and 32%, respectively. Donor source, prior
autologous HCT, prior myelosuppressive chemother-
apy, patient age, IPSS risk, or presence of aGVHD or
cGVHD did not impact the incidence of NRM.
There were 156 documented episodes of blood-
borne infections among 64 patients. Ninety-six
(62%) of these episodes were bacterial, of which 48%
were because of coagulase negative Staphylococcus spe-
Figure 1. Relapse-free survival (years) by disease subgroup.cies. Fifty-five (35%) episodes were viral, of which
most (87%) were because of CMV reactivation. Four
patients experienced documented CMV pulmonary
disease, 5 patients had BK virus in their urine, and 1
patient developed an acute hepatitis C infection. Fun-
gemia was documented in 5 patients.
DISCUSSION
The development of nonmyeloablative or RIC
regimens has broadened the eligibility of allogeneic
HCT to patients who otherwise might not be offered
this potentially curative modality. This study details
the results of the largest published series of MDS
andMPD patients who were given a nonmyeloablative
or RIC regimen before receiving unmanipulated
allogeneic hematopoietic cells. All patients were con-
sidered at high risk to undergo myeloablative condi-
tioning because of age, comorbid medical conditions,
or failed autologous or allogeneic HCT.
Overall, the conditioning regimen of flu and
low-dose TBI was well tolerated, with a 100-day and
200-day mortality of 11% and 21%, respectively. Re-
ceipt of a prior myeloablative HCT was not a risk
Figure 2. Overall Survival (years) by disease subgroup.
Figure 3. Relapse incidence (years) by disease subgroup.
252 G. G. Laport et al.factor for increased NRM in this heavily pretreated
subset, which confirms the low toxicity of the regimen.
Donor type, specifically grafts from unrelated donors,
also did not an adversely affect NRM as has been
observed with myeloablative regimens. With longer
follow-up, however, the NRM increased to 32% at 3
years. The median age of our patients was 59 years
old, and older recipient age is a known negative prog-
nostic factor for NRM and OS [1,2,11,12].
In our series, relapse represented the leading cause
of death. This could be partly explained by the fact that
over half of the patients had treatment-related MDS
(t-MDS), CMML, and transformed AML, malignan-
cies inherently associated with poor prognoses. Of
the de novo MDS patients, approximately 43% had
intermediate-2 or high risk IPSS scores. Type of donor
(related versus unrelated) did not significantly impact
relapse incidence. However, RIC regimens rely pri-
marily on the graft-versus-tumor effect to confer
remissions with the intensity of the conditioning regi-
men also being an important factor in controlling
disease kinetics in this patient population. Our immu-
Figure 4. Relapse-free survival (years) by IPSS grouping. There was
no significant difference in relapse-free survival (RR5 1.38,P5 .37).
Figure 5. Relapse/progression incidence (years) by IPSS grouping.
The patients in the intermediate-2/high-risk group had a signifi-
cantly higher risk of relapse/progression (RR 5 2.92, P 5 .04).nuosuppressive conditioning regimen offered minimal
cytoreduction and was mainly immunosuppressive,
which also could have contributed to relapse.
Two published retrospective series, 1 from the
European Bone Marrow Transplant group and the
other from the Dana Farber Cancer Institute, retro-
spectively compared the outcomes of patients with
hematologic malignancies including MDS who
received either a myeloablative or a RIC regimen
[13,14]. Both reports showed significantly decreased
relapse rates in the myeloablative group but at the
expensive of higher NRM. Thus, survival outcomes
were comparable between the 2 types or regimens.
These observations of lower NRM but higher relapse
among RIC recipients reinforces that some degree of
cytoreduction in the conditioning regimen is necessary
to control disease prior to the establishment of the
graft-versus-tumor effect.
The incidence of aGVHD and cGVHD in this
trial was comparable to other published studies using
RIC with this patient population. Type of donor did
not impact the rates of either aGVHD or cGVHD in
our study. The incidence of cGVHD varies widely in
the literature after RIC transplantation, which could
be accounted for by variable lengths of follow-up and
different sample sizes [15-22]. In this report, the
occurrence of cGVHD but not aGVHD was associ-
ated with a lower risk of relapse/progression. This
finding is in accordance with other reports and con-
firms the crucial role of the GVL effect. In a prospec-
tive series of 37 patients with AML and MDS,
a Spanish group reported a significantly lower risk of
disease progression in patients who developed
aGVHD or cGVHD compared to those who did not
(13% versus 58%) after receiving an RIC regimen of
flu and busulfan [20]. In a large retrospective series
of 221 patients with hematologic malignancies from
the Fred Hutchinson Cancer Research Center, an as-
sociation with cGVHD and a reduced relapsed inci-
dence was also observed with the beneficial effects
most notable in the MDS and AML patients [23]. In
contrast, a recent report from M.D. Anderson on
112 patients with AML and MDS who received flu
and melphalan as a preparative regimen reported no
effect of cGVHD on progression or survival with
aGVHD negatively impacting survival [24].
HCT at the time of leukemic progression portends
a poor prognosis, but the optimal timing of HCT for
early MDS remains unclear. Over half of the patients
in our series (58%) received myelosuppressive chemo-
therapy prior to HCT. Compared to patients who did
not receive myelosuppressive chemotherapy, no
advantage was seen in terms of survival, relapse, or
NRM. However, our results might be affected by
selection bias as this was a retrospective analysis. Pre-
viously published transplant series have demonstrated
advantages for patients who entered transplant with
Allogeneic Reduced Intensity Conditioning 253Table 4. Univariate Analysis of Risk Factors
OS (111 events) RFS (114 events)
Relapse/prog
(64 events) NRM (50 events)
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Disease group
AML (n 5 49) 1.0 1.0 1.0 1.0
MDS (n 5 40) 0.86 (0.5-1.4) 0.86 (0.5-1.4) 0.64 (0.3-1.2) 1.27 (0.6-2.6)
t-MDS (n 5 25) 0.83 (0.5-1.4) 0.82 (0.5-1.4) 0.70 (0.3-1.5) 1.01 (0.4-2.4)
MPD (n 5 27) 0.61 (0.3-1.1) .53 0.63 (0.4-1.1) .60 0.41 (0.2-1.0) .14 0.98 (0.4-2.2) .20
CMML (n 5 7) 0.74 (0.3-1.9) 0.84 (0.4-2.0) 1.28 (0.5-3.1) 0.0 (undefined)
Patient age
\60 yo (n 5 78) 1.0 1.0 1.0 1.0
$60 yo (n 5 70) 0.71 (0.5-1.0) .07 0.73 (0.5-1.1) .10 0.74 (0.5-1.2) .24 0.72 (0.4-1.3) .25
Donor relation
MRD (n 5 75) 1.0 1.0 1.0 1.0
URD (n 5 73) 1.32 (0.9-1.9) .15 1.25 (0.9-1.8) .23 1.07 (0.7-1.8) .78 1.53 (0.8-2.7) .14
Patient sex
Male (n 5 98) 1.0 1.0 1.0 1.0
Female (n 5 50) 0.79 (0.5-1.2) .24 0.79 (0.5-1.2) .24 0.82 (0.5-1.4) .47 0.75 (0.4-1.4) .34
Donor sex
Male (n 5 75) 1.0 1.0 1.0 1.0
Female (n 5 73) 0.93 (0.6-1.3) .69 0.86 (0.6-1.2) .41 0.82 (0.5-1.3) .44 0.90 (0.5-1.6) .72
Prior autologous HCT
No (n 5 130) 1.0 1.0 1.0 1.0
Yes (n 5 18) 0.94 (0.5-1.7) .83 0.88 (0.5-1.6) .67 0.85 (0.4-1.9) .67 0.93 (0.4-2.2) .87
Prior myelosuppressive
chemotherapy (unknown
for 3 patients)
No (n 5 61) 1.0 1.0 1.0 1.0
Yes (n 5 84) 1.20 (0.8-1.8) .34 1.13 (0.8-1.6) .54 1.47 (0.9-2.5) .14 0.81 (0.5-1.4) .46
In CR at transplant
(unknown for 17 patients)
No (n 5 90) 1.0 1.0 1.0 1.0
Yes (n 5 41) 1.04 (0.7-1.6) .86 0.95 (0.6-1.4) .80 0.93 (0.5-1.6) .79 0.97 (0.5-1.9) .93
Chronic GVHD
(clinical extensive, as time-
dependent covariate)
No (n 5 93) 1.0 1.0 1.0 1.0
Yes (n 5 5) 0.73 (0.5-1.2) .19 0.68 (0.4-1.2) .16 0.42 (0.2-1.0) .04 1.02 (0.5-2.1) .96
IPSS risk
(among de novo MDS only,
unknown for 1 patient)
Low (n 5 22) 1.0 1.0 1.0 1.0
High (n 5 17) 1.05 (0.5-2.1) .89 1.38 (0.7-2.8) .37 2.92 (1.0-8.6) .04 0.69 (0.2-2.0) .47
OS indicates overall survival; RFS, relapse-free survival; NRM, nonrelapse mortality; CR, complete remission; Relapse/prog, relapse/progres-
sion; HCT, hematopoietic cell transplantation; IPSS, International Prognostic Scoring System; MRD, matched related donor; URD,
unrelated donor; MDS, de novo myelodysplastic syndrome; t-MDS, treatment-related myelodyplastic syndrome; AML, acute myelogenous
leukemia after antecedent myelodysplastic syndrome or myeloproliferative disorder; MPD, myeloproliferative disorder; CMML, chronic
myelomonocytic leukemia; yo: years old.low disease burdens as increased numbers of blasts in
the blood or bone marrow have been described as 1
of the most important risk factors for relapse
[12,25,26]. However, the value of cytoreduction in
this setting remains controversial, and most prior
reports have shown no benefit.
Direct comparison of the 5 subgroups in this
report is difficult because of the relatively small sample
sizes of each group. CMML typically contains features
of both MDS and MPD and carries a median survival
of only 6-24months, depending on prognostic features
[27]. Of the 7 patients with CMML, 5 patients haveexpired from relapse. Three reports utilizing primarily
myeloablative regimens for CMML patients report
DFS ranging from 18%-41%, with relapse incidences
ranging from 23%-63%. Transplantation early in the
disease course and having few or no comorbidities pre-
dicted for a better outcome [28-30].
The prognosis for patients with t-MDS is poor
with a median survival of 4 months and the efficacy
of HCT for this specific population is difficult to assess
as most of the data reported is combined with primary
MDS patients [31]. In our series, the 25 patients with
t-MDS had a PFS and OS of 29% and 27%, which is
254 G. G. Laport et al.similar to the outcomes of the 40 patients with primary
MDS. The relapse rate of 40% was identical between
both groups. The RFS of 29% is comparable to the
the few published reports of myeloablative allogeneic
HCT specifically for t-MDS with RFS ranging from
8%-30%. Our NRM of 31% at 3 years, however,
appeared significantly less, as these previously men-
tioned myeloablative reports detailed NRM rates
ranging from 42%-58% [1,5,32].
As seen with MDS patients, allogeneic HCT also
remains the only curative treatment for MPD patients.
The prognosis varies widely among idiopathic myelo-
fibrosis, PV, and essential thrombocythemia and allo-
geneic HCT has historically been offered later in the
course of the disease. Previously published series
detailing the feasibility of myeloablative HCT for
MPD patients demonstrate long-term disease-free
survival (DFS) with actual reversal of myelofibrosis in
the marrow. Overall survival (OS) figures have ranged
from 38%-47% at 5 years, butNRMhas been reported
as high as 48% [3,4,33,34]. Our series contained 27
patients with MPD, among whom 12 had myelofibro-
sis. For all 27 patients, the 3-year RFS and OS were
37% and 43%, respectively, with an actuarial relapse
rate and NRM of 26% and 37%, respectively. These
statistics are comparable to previously published mye-
loablative series, and it appears NRM was not signifi-
cantly improved with the conditioning regimen
chosen. Relapse represented the leading cause of death.
In summary, our regimen of low-dose TBI and
fludarabine was well tolerated considering our older
patient population, and certain subsets of patients
have benefited with long-term RFS. Relapse, however,
was the major cause of treatment failure, and this par-
ticular regimen may not have conferred enough cyto-
reduction for adequate disease control. Novel regimens
that have incorporated radioimmunoconjugates show
promising results [35]. Allogeneic HCT remains the
only curative modality for MDS and MPD, with non-
myeloablative or RIC regimens clearly benefiting this
older population by reducing upfront toxicity. How-
ever, further investigation is warranted to determine
the optimal regimen with adequate dose intensity and
low toxicity.
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